Spots Global Cancer Trial Database for Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
Official Title: A Multicenter, Open-label, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-653 in Treatment of Patients With Advanced Malignant Solid Tumors and Tenosynovial Giant Cell Tumor
Study ID: NCT05277454
Interventions
Study Description
Brief Summary: To evaluate the safety and tolerability of HMPL-653 in patients with advanced solid tumors who have failure of standard of care or can not tolerate standard of care or those with TGCT, and to determine the maximum tolerated dose (MTD) and/or the recommended phase II clinical study dose (RP2D) of HMPL-653 in patients with advanced solid tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Jilin Provincial Cancer Hospital, Chang chun, , China
Harbin Medical University Cancer Hospital, Harbin, , China
Linyi Cancer Hospital, Linyi, , China
Henan Cancer Hospital, Zhengzhou, , China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, , China
Contact Details
Name: Ying Cheng, Prof
Affiliation: Jilin Provincial Cancer Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
